These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 20140862)
21. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066 [TBL] [Abstract][Full Text] [Related]
22. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells. Tsai HF; Tsai HJ; Hsieh M Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352 [TBL] [Abstract][Full Text] [Related]
23. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance. Li X; Liu H; Fischhaber PL; Tang TS Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252 [TBL] [Abstract][Full Text] [Related]
24. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Perez MK; Paulson HL; Pittman RN Hum Mol Genet; 1999 Dec; 8(13):2377-85. PubMed ID: 10556285 [TBL] [Abstract][Full Text] [Related]
25. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease]. Jia D; Jiang H; Tang B Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526 [TBL] [Abstract][Full Text] [Related]
26. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis. Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985 [TBL] [Abstract][Full Text] [Related]
27. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Mueller T; Breuer P; Schmitt I; Walter J; Evert BO; Wüllner U Hum Mol Genet; 2009 Sep; 18(17):3334-43. PubMed ID: 19542537 [TBL] [Abstract][Full Text] [Related]
28. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models. Hübener J; Riess O Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840 [TBL] [Abstract][Full Text] [Related]
29. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy. Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604 [TBL] [Abstract][Full Text] [Related]
30. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. Haacke A; Hartl FU; Breuer P J Biol Chem; 2007 Jun; 282(26):18851-6. PubMed ID: 17488727 [TBL] [Abstract][Full Text] [Related]
31. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease. Chang WH; Tien CL; Chen TJ; Nukina N; Hsieh M Neurosci Lett; 2009 Apr; 454(2):152-6. PubMed ID: 19429074 [TBL] [Abstract][Full Text] [Related]
32. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362 [TBL] [Abstract][Full Text] [Related]
33. CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration. Liman J; Deeg S; Voigt A; Voßfeldt H; Dohm CP; Karch A; Weishaupt J; Schulz JB; Bähr M; Kermer P J Neurochem; 2014 Jun; 129(6):1013-23. PubMed ID: 24548080 [TBL] [Abstract][Full Text] [Related]
34. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD. Jana NR; Nukina N Neurotox Res; 2004; 6(7-8):523-33. PubMed ID: 15639784 [TBL] [Abstract][Full Text] [Related]
35. Dynamic expression of Hsp27 in the presence of mutant ataxin-3. Chang WH; Cemal CK; Hsu YH; Kuo CL; Nukina N; Chang MH; Hu HT; Li C; Hsieh M Biochem Biophys Res Commun; 2005 Oct; 336(1):258-67. PubMed ID: 16126176 [TBL] [Abstract][Full Text] [Related]
37. p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin-3 to the proteasome. Wang H; Jia N; Fei E; Wang Z; Liu C; Zhang T; Fan J; Wu M; Chen L; Nukina N; Zhou J; Wang G J Neurochem; 2007 Jun; 101(6):1651-61. PubMed ID: 17302910 [TBL] [Abstract][Full Text] [Related]
38. Caring for Machado-Joseph disease: current understanding and how to help patients. D'Abreu A; França MC; Paulson HL; Lopes-Cendes I Parkinsonism Relat Disord; 2010 Jan; 16(1):2-7. PubMed ID: 19811945 [TBL] [Abstract][Full Text] [Related]
39. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse. Wang HL; Hu SH; Chou AH; Wang SS; Weng YH; Yeh TH Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954 [TBL] [Abstract][Full Text] [Related]
40. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse. Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]